Agenus Inc. (NASDAQ: AGEN) plunged over 5.36% in early trading session on Friday as the company stated that it will present new results on its expanding portfolio of clinical-stage immuno-oncology initiatives at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will take place November 8-12 in Boston, MA and remotely.
New findings from the Phase 1 research of botensilimab (a multifunctional Fc-enhanced anti-CTLA-4) in cold (immunotherapy-resistant) cancers will be presented during a new immunotherapies oral plenary session on Saturday, November 12th at 10:50am ET. Three more presentations will feature fresh data on the mechanisms behind botensilimab’s differentiated and increased anti-tumor immunity, as well as an update on the ongoing Phase 2 study of AGEN1423, an anti-CD73-TGF-trap bifunctional antibody in conjunction with balstilimab (anti-PD-1).
Agenus also announced today that Dhan Chand, PhD, Head of Drug Discovery at Agenus, has been selected to talk on the topic of improved CTLA-4 blocking at the SITC Targets for Cancer IO Deep Dive Series on Wednesday, October 5, from 2:00 pm – 4:00 pm ET. To register for the webinar, go to the SITC website’s Educational and Scientific Programs area. Dr. Chand’s selection in a very competitive process demonstrates his leadership and emphasizes the focus on botensilimab, as well as the field’s recognition for the essential role CTLA-4 plays in anti-tumor immunity and the scientific contributions and knowledge achieved by the Agenus team.
